Xcout Intel
AbTx competitors & alternatives
The 12 closest competitors and alternatives to AbTx among biotech companies — ranked by similarity to what AbTx actually does, not by market-cap band.
Subscribe to see AbTx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About AbTx
AbTx (Antibody for Therapy) is a preclinical-stage biotechnology company headquartered in Dijon, France. The firm designs personalized medicine biotherapies in oncology based on antibody-drug conjugates (ADCs) to treat incurable cancers.
AbTx at a glance
AbTx is a biotech company headquartered in France. Its most recent funding round, Seed, raised $1.9M in October 2026. Xcout tracks 1 named person at AbTx, including Meddy El Alaoui (co-founder).
AbTx leadership
- Meddy El Alaouico-founder
AbTx funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $1.9M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent AbTx news
Top 12 AbTx competitors
Ranked by semantic similarity — how close each company is to AbTx by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
DCx Biotherapeutics is a Canadian preclinical-stage biotechnology company developing precision oncology therapeutics and precision drug conjugates to target genetically defined cancers. The company focuses on addressing root drivers and key cellular interdependencies of cancer lesions.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Biotechnology
A2 Biotherapeutics, Inc. is a clinical-stage biotechnology research company headquartered in Agoura Hills, California. The company develops precision T-cell therapies designed to target solid tumors while sparing healthy tissue.
Biotechnology
Celyad Oncology is a biopharmaceutical company headquartered in Mont-Saint-Guibert, Belgium, focused on the development of innovative therapies.
Similar biotech company
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Biotechnology
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Life Science
Synthorx, Inc., founded in 2014, is a biotechnology company headquartered in La Jolla, California, that engineered expanded genetic alphabet technologies to discover and develop novel protein therapeutics.
Biotechnology
Affini-T Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, specializing in the development of precision immunotherapies and T-cell therapies for cancer patients.
Similar biotech company
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Biotechnology
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Similar biotech company
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Biotechnology
Go Therapeutics, Inc. is a biopharmaceutical company applying advances in glycoproteomics to develop novel antibody-based cancer therapies and immuno-oncology treatments. Headquartered in Natick, Massachusetts, the company has been active since 2014.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of AbTx and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for AbTxand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →